Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07255638 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 8 → 12 locations
    • Secondary endpoints: details revised at 1 of 19 entries
    • Eligibility criteria expanded, about 3 words
  2. Trial sites expanded: 4 → 8 locationsv4
  3. Study sites: 1 to 4v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 1, 2025 to Dec 9, 2025
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a non-interventional study assessing the effectiveness of avapritinib (BLU-285) in the management of ISM in real-world settings in Germany. The study also seeks to address the existing data gap in the natural history and management of participants with ISM. The study is designed to follow each participant up to a maximum of 24 months.
Trial Details
NCT Number NCT07255638
Lead Sponsor Blueprint Medicines Corporation
Conditions
(from sponsor)		 Indolent Systemic Mastocytosis
Related terms Mastocytosis, Mastocytosis, Systemic
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov